Clinical relevance that cyclin E-CDK2 signaling could be a therapeutic target is more strengthened by our analysis of the public gene expression profiling data sets from HR-positive breast cancer patients, even though they were not exposed to CDK4/6 inhibitors. The gene discussed is CCNE1; the disease is breast cancer.